Page 2 - Josh Wooley News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers focus on use of psilocybin to treat Parkinson’s disease
Pharma company also plans to investigate psychedelic therapies for multiple sclerosis
by Clara Furlong
Silo Pharmaceuticals
In 2006, Johns Hopkins researchers published a groundbreaking study on the effects of a single dose of psilocybin, a naturally occurring psychedelic compound found in more than 200 species of mushrooms. The team had to set up “unusually rigorous scientific conditions and measures” amid highly restrictive regulatory policies, which were partially due to unfavorable media coverage from the recreational use of “shrooms” in the 1960s and ‘70s that had resulted in misperceptions of risk.
The landmark study provided a scientific framework to better understand how hallucinogenic drugs target the brain’s serotonin receptors, and the researchers announced future plans to investigate how psilocybin might be used to treat conditions like cancer-related anxiety and depre ....

United States , San Francisco , Josh Wooley , Johns Hopkins , Eric Weisblum , University Of California , Silo Pharmaceuticals , University Of Maryland Baltimore , Maastricht University Of The Netherlands , Drug Administration , Behavioral Sciences , Department Of Psychiatry , Associate Professor , His Bonding , Neuropsychiatric Disorders , Chief Executive , Maryland Baltimore , Maastricht University , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , ஜோஷ் கம்பளி , ஜான்ஸ் ஹாப்கின்ஸ் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , ஸைலொ மருந்துகள் , பல்கலைக்கழகம் ஆஃப் மேரிலாந்து பால்டிமோர் , நடத்தை அறிவியல் ,